Aelis Farma S.A.
AELIS.PA
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.89M
Close$
Share Statistics
| Market cap | $10.89 Million |
|---|---|
| Enterprise Value | $9.48 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.47 |
| Beta | 0.62 |
| Outstanding Shares | 13,705,000 |
Return
| Return on Equity | -591.54% |
|---|---|
| Return on Assets | -150.79% |
| Return on Invested Capital | -272.12% |
Valuation & Multiples
| P/E Ratio | -2.42 |
|---|---|
| PEG | 5.48 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2.39 |
| Enterprise Value to EBIT | -0.66 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.55 |
| Debt to Equity | 2.42 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 15, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
April 5, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Aelis Farma S.A.
16 employees
CEO: Pier Vincenzo Piazza Aelis Farma S.A., a French biotechnology company founded in 2013 and headquartered in Bordeaux, is dedicated to the discovery and development of treatments for brain-related illnesses. The firm's research pipeline primarily focuses on si...